<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049101</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000257808</org_study_id>
    <secondary_id>MSKCC-02039</secondary_id>
    <secondary_id>NCI-5371</secondary_id>
    <nct_id>NCT00049101</nct_id>
  </id_info>
  <brief_title>Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I/II Study Of OSI-774 In Combination With Oxaliplatin, And 5-Fluourouracil In Patients With Metastatic Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the&#xD;
      enzymes necessary for tumor cell growth. Combining erlotinib with combination chemotherapy&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combining erlotinib with oxaliplatin,&#xD;
      leucovorin, and fluorouracil in treating patients who have metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of erlotinib when administered with oxaliplatin,&#xD;
           leucovorin calcium, and fluorouracil in patients with metastatic colorectal cancer.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine any antitumor activity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the objective response rate and response duration in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of erlotinib.&#xD;
&#xD;
        -  Phase I: During the first week of the first course only, patients receive oral erlotinib&#xD;
           daily alone. Patients then begin the regular schedule comprising oral erlotinib daily,&#xD;
           oxaliplatin IV over 2 hours on day 1, and leucovorin calcium IV over 2 hours and&#xD;
           fluorouracil IV over 22 hours on days 1 and 2. Treatment repeats every 2 weeks for at&#xD;
           least 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive erlotinib at the MTD plus oxaliplatin, leucovorin calcium,&#xD;
           and fluorouracil as in phase I. Erlotinib may be administered alone if toxicity is&#xD;
           caused by oxaliplatin, leucovorin calcium, and fluorouracil.&#xD;
&#xD;
      Patients are followed for at least 6 months or until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 4-18 patients will be accrued for phase I of this study within&#xD;
      1-4 months. A total of 50 patients will be accrued for phase II of this study within 10&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed colon or rectal cancer&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Unidimensionally measurable disease required for phase II only&#xD;
&#xD;
               -  At least 20 mm by x-ray, CT scan, MRI, or photography&#xD;
&#xD;
               -  The following are not considered measurable:&#xD;
&#xD;
                    -  Pleural effusion or ascites&#xD;
&#xD;
                    -  Osteoblastic lesions&#xD;
&#xD;
                    -  Evidence of disease on bone scan alone&#xD;
&#xD;
                    -  Progressive irradiated lesions alone&#xD;
&#xD;
                    -  Bone marrow involvement&#xD;
&#xD;
                    -  Brain metastases&#xD;
&#xD;
                    -  Malignant hepatomegaly by physical exam alone&#xD;
&#xD;
                    -  Chemical markers (e.g., carcinoembryonic antigen)&#xD;
&#xD;
               -  Recurrent disease after surgery or radiotherapy is considered measurable as long&#xD;
                  as the following criteria are met:&#xD;
&#xD;
                    -  At least 4 weeks since prior surgery or radiotherapy&#xD;
&#xD;
                    -  Measurable disease exists outside the radiation port or clear progression&#xD;
                       exists within the radiation port&#xD;
&#xD;
          -  Tissue accessible for immunohistochemical evidence of epidermal growth factor receptor&#xD;
             expression from a metastatic site (phase II only)&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension (systolic blood pressure greater than 150 mm Hg)&#xD;
&#xD;
        Opthalmic&#xD;
&#xD;
          -  No abnormalities of the cornea (e.g., severe dry eye syndrome or Sjogren's syndrome)&#xD;
&#xD;
          -  No congenital abnormality (e.g., Fuch's dystrophy)&#xD;
&#xD;
          -  No abnormal slit-lamp examination using vital dye (e.g., fluorescein or Bengal-Rose)&#xD;
&#xD;
          -  No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear-production&#xD;
             test)&#xD;
&#xD;
          -  Mild dry eye syndrome allowed if patient can use artificial tears and ophthalmologist&#xD;
             concurs&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in an inability to take oral medication or&#xD;
             a requirement for IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Must be able and willing to undergo a mediport insertion&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except previously excised and inactive&#xD;
             basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biological&#xD;
             composition to erlotinib or other study drugs (e.g., epidermal growth factor&#xD;
             inhibitors like cetuximab)&#xD;
&#xD;
          -  No significant traumatic injury within the past 3 weeks&#xD;
&#xD;
          -  No peripheral neuropathy grade 2 or greater&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other uncontrolled concurrent illness that would preclude study entry&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Phase I:&#xD;
&#xD;
               -  Prior chemotherapy allowed&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
               -  Prior adjuvant therapy allowed if disease progresses during adjuvant therapy&#xD;
&#xD;
               -  No prior oxaliplatin&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies (commercial or investigational)&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard B. Saltz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

